FDA Scrutiny on Sarepta - Search News

Order byBest matchMost fresh

FDA, Sarepta and gene

· 6d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

U.S. regulators asked Sarepta Therapeutics (SRPT.O) on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treat...

Continue reading

· 2d · on MSN

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Sarepta Concedes to FDA Request, Suspends US Shipments of Elevidys

InnovationRx: Sarepta Blinks In Showdown With FDA

The latest twist in the saga followed a decision by Children’s Hospital Los Angeles to halt use of the drug while it was facing regulatory uncertainty.

Continue reading

Sarepta falls after gene therapy maker pauses Elevidys shipments in US

Sarepta pares gains as report suggests an ‘arduous’ path for Duchenne drug

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

2d

Sarepta Therapeutics cuts Durham jobs amid mass layoffs, FDA scrutiny

A Massachusetts biotechnology company is laying off 21 employees in Durham amid a broader restructuring and pressure from federal regulators.